Ref: Syn/CS/SE/IP/2022-23/April/10

Syngene International Limited
Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.
T +91 80 6891 8000
F +91 80 6891 8808
CIN: L85110KA1993PLC014937
www.syngeneintl.com

April 27, 2022

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	**Scrip Symbol: SYNGENE**

Dear Sir/Madam,

Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter and year ended March 31, 2022. The Company will use this presentation for any meeting scheduled with analysts or institutional investors up to June 30, 2022.

The above-mentioned Investor Presentation will also be available on website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

PRIYADARSHINI MAHAPATRA

Digitally signed by PRIYADARSHINI MAHAPATRA
DN: c=IN, o=Personal, pseudonym=bc2eb3d598e4b4695dfab584d8c4954317f2c9b276b0ead69f4b6de415c5150d, 2.5.4.20=3b3032863a60d6cf503dc962d0b81de07d5cef26229a00b3f723a1ef57ab0005, postalCode=751015, st=ODISHA, serialNumber=df67e39aa5435d22f718c22d0516d97afb12085364f41860285e06c72d0c9992, cn=PRIYADARSHINI MAHAPATRA
Date: 2022.04.27 15:13:52 +05'30'

Priyadarshini Mahapatra
Company Secretary and Compliance Officer

Enclosed: Investor Presentation.

Syngene

Putting Science to Work

Investor Presentation

April 2022

Safe harbour

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.

Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.

Neither the company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Contents

1 Operating Highlights

2 Syngene – Putting Science to Work

3 Strategic Advantages

4 Financials

5 Shareholding and Share Information

1 Operating Highlights

Q4 FY22 performance

Operating Highlights

- Growth was driven by solid delivery across all divisions.Development Services had a particularly strong quarter as it caught up on projects postponed due to supply chain and other Covid-related disruption, in addition to planned work.
- Phase three of the expansion plan at the Hyderabad research facility was completed
- Company won two prestigious industry awards
  - At the CMO Leadership Awards 2022 we ranked top in all the six core award categories - quality, expertise, compatibility, capabilities, reliability, and service.
  - Golden Peacock Award for Excellence in Corporate Governance for the year 2021, awarded by the Institute of Directors.

Q4 Financial Highlights

- Revenue from operations increased by 15% year-on-year
- EBITDA growth of 13% year-on-year

Total Revenue **Rs. 7,728 Mn**	EBITDA **Rs. 2,650 Mn**
Profit After Tax **Rs. 1,478 Mn**	EBITDA **Margin at 34%** PAT **Margin at 19%**

Full year performance FY22

Operating Highlights

- Syngene's Integrated Drug Discovery (IDD) platform, made a positive contribution to Discovery Services during the year as the number of IDD projects increased by 40% compared to the previous year.
- Extended and expanded research collaboration with Amgen. Syngene will also build and operate a dedicated laboratory to accelerate the scale-up of small molecule projects.
- Development and Manufacturing businesses included expanding the biopharma manufacturing capacity by commissioning a cGMP microbial facility and expanding of the mammalian cell manufacturing facility.
- In small molecule development services, the oligonucleotide and highly potent API capabilities were both extended and plans are on track for the Mangalore manufacturing plant to achieve a major regulatory approval thus opening it up to a broader scope of projects.
- Worked with clients on diagnostics, treatments and vaccines related to the coronavirus. The Company also manufactured remdesivir under a voluntary licence from Gilead. This manufacturing will continue for as long as the pandemic persists.

FY22 Financial Highlights

- Revenue from operations increased by 19% year-on-year
- EBITDA growth of 15% year-on-year

Total Revenue **Rs. 26,570 Mn**	EBITDA **Rs. 8,489 Mn**
Profit After Tax* **Rs. 4,211 Mn**	EBITDA **Margin at 32%** PAT **Margin* at 16%**

*Note :Net profit for FY22 was Rs. 3,958 Mn inclusive of exceptional item of Rs. 253 Mn.| PAT and PAT margins without accounting for exceptional item

FY23 guidance

Parameter	FY23 Guidance
Revenue from operations	Expected to grow at least in the mid-teens
EBITDA Margin	In light of positive demand environment for CRO and CDMO services, expect to step up investments in new scientific capabilities, IT, digitisation and commercial activities. This step up in investment, along with resumption of travel and other business activities post-pandemic in an inflationary environment, is likely to put pressure on margins during the course of the year. In aggregate, expect to deliver an EBITDA margin around 30%. With this step up in operating investment, the Company expects to be well positioned and anticipates seeing improved growth and operating leverage from FY24.
PAT Margins and Growth (before exceptional items)	With the SEZ tax benefit for key operating units reducing this year and in coming years, the Company expects the effective tax rate to increase by 200 to 300 basis points in FY23, creating some dilution in the PAT margin. PAT growth rate for the full year expected to be in single digits.

2 Syngene – Putting Science to Work

Syngene

Putting science to work

Who we are and what we do

Integrated solution provider across research, development manufacturing covering pharma, biotech, nutrition, animal health, consumer goods and specialty chemical.

Working with clients from around the world to find solutions to their scientific challenges for small and large molecules while improving productivity, speeding up time to market and lowering cost of innovation.

Innovative culture driven by the expertise of a highly qualified team of 6,000+ employees and supported by state-of-the-art infrastructure and market-leading technology



Well established in scientific research and development, emerging presence in commercial manufacturing of small molecules and large molecules

Syngene key facts and figures

420+
active clients

15
collaborations
with top 20 pharmaceutical companies

400+
Patents
held with clients

2 Mn sq. ft.
of World class infrastructure, qualified to meet international standards

Rs. 40,381 Mn
Cum. Investment

Rs. 26,570 Mn
FY22 Revenue

Rs. 4,211 Mn
FY22 PAT before exceptional item

~5300
talented team of scientists
Including ~500 PhDs

All figures are as on March 31, 2022, unless otherwise specified

International accreditations

- USFDA,OHSAS 18001,
- GLP, cGMP, AAALAC & CPCSEA Certified Facilities
- CAP accreditation, ISO/IEC 27001:2013 accreditation
- EMA and PMDA approved, AAALAC Accredited facility
- The safety assessment laboratories and large molecule bioanalytical lab are ISO IEC 17025:2017 certified by the National Accreditation Board for Testing and Calibration Laboratories (NABL).

Our experience spans multiple industry segments and partnerships with global leaders across the world

Large & Mid-Sized BioPharma

Bristol Myers Squibb™

Albireo

gsk

SANOFI

Johnson & Johnson

MERCK

AMGEN

abbvie

Emerging BioPharma (EBP)

Clinical-stage company creating novel medicines targeting

G protein-coupled receptors (GPCRs)

rodin THERAPEUTICS

sosei HEPTARES

PharmAust LIMITED

Genmab

ASCENEURON A Neurodegeneration Therapeutics Company

European clinical-stage biopharmaceutical focused on Oncology

Animal Health

zoetis

MERCK

BAYER

AgroChem

FMC

Leading China based crop protection company

Large Japanese chemical company

Large MNC focussed on Agriculture & Nutrition segments

Consumer products

Global food and beverage company

Unilever

Our journey so far



Foundation
- Operations started
- Expansion of R&D Lab
- Granted 100% EOU status by the Government of India

Expansion
- Expanded service offerings to include chemical development, safety assessment, biologics development
- Collaboration with BMS to set up BBRC, Syngene's first dedicated R&D Center

Globalization and strategic collaboration
- Expanded into formulations development
- Contract with Endo Pharmaceuticals to develop novel anti cancer biological therapeutic molecules
- Collaboration with Baxter to set up a dedicated R&D center
- Extension of collaboration with BMS; Merger of Clinigene
- Crossed annual turnover of Rs. 5 Billion

IPO and further collaborations
- IPO and listing
- Collaboration with Amgen set up a dedicated R&D center

Continued investments and growth
- Expanded collaboration with BMS; Baxter and Amgen
- Expansion of IDD platform
- Laboratory capacity expansion in Bangalore, Hyderabad
- Expansion in Mangalore for commercial API mfg.
- Capacity and capability addition in Biologics manufacturing

Our divisions

Research business

Discovery Services

Engaged in early-stage research, from target identification to delivery of drug candidates for further development

Capabilities include Chemistry, Biology, Safety Assessment, and Research Informatics for small molecules; recombinant DNA engineering, cell line development, Next Generation Sequencing, and protein sciences for large molecules

Dedicated R&D Centers

Dedicated R&D facilities for strategic clients providing exclusive access to research teams, infrastructure, and project management to support the client's R&D requirements.

Development and Manufacturing business

Development Services

Engaged in activities from pre-clinical to clinical trials, including drug substance and drug product development, and associated services to demonstrate the safety, tolerability, and efficacy of the selected drug candidate, cGMP compliant manufacturing of clinical supplies, and registration batches for small molecules

Manufacturing Services

Engaged in the manufacturing of small and large molecules for commercial supplies through cGMP-compliant facilities, a state-of-the art API manufacturing campus and a biologics manufacturing facility

Our collaboration models

1

Dedicated R&D Labs

- Dedicated scientific and support teams work exclusively on the client's project
- Clients are provided with customized and ringfenced infrastructure
- Long-term strategic alliances that last usually five years or more

2

FTE

- Pre-defined numbers of scientific personnel from pre-determined disciplines work full-time on client projects
- Deliverables and team composition evolve as the project advances
- Agreements are typically renewed annually

3

FFS

- Client collaboration to deliver agreed services within a defined scope.
- Flexible, on demand personnel and research infrastructure deployed to achieve the project objectives
- Engagements may be short or long-term

4

Productivity based model

- Offer the services directly linked to productivity generated by our team

5

Risk-reward

- Across a portfolio of stage gate-driven research projects
- Client benefits from reduced upfront payments in exchange for significant success-based milestone payments against pre agreed criteria

6

Delivery based contract for CDMO business

- Per Kg Per Batch model with built in milestones progressing towards achievement of outcome and delivery of drug substance, drug product

… and are open to any single or combination of above

Our dedicated R&D centers exemplify the success of our long-term strategic alliances

Bristol Myers Squibb™

- **600+** scientists
- **300,000+ sq. ft.** laboratory space
- Largest R&D Center in Asia for BMS (est.d 2009).
- Integrated drug discovery and development in multiple therapeutic areas, including cardiovascular, fibrosis, immunology, oncology, translational medicine and pharmaceutical development
- Produced >10 drug candidates for further study and advanced new compounds for first-in-human studies

Baxter

- **ca.200** scientists
- **70,000 sq. ft.** laboratory space
- Dedicated R&D Center in India for Baxter (est.d 2013).
- R&D activities centered on product and analytical development, preclinical evaluation in parenteral nutrition and renal therapy
- Collaboration expanded to include microbiology research and preclinical assessment projects for medical devices
- Delivered four new product development projects for registration in the US and European Union markets.

AMGEN

- **ca.170** Scientists
- **60,000 sq. ft.** laboratory space
- Exclusive R&D Center for Amgen Inc. in India (est.d 2016)
- Focus on medicinal & process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research and pharmaceutical development
- Operational excellence initiatives were introduced to improve productivity across functional areas.

Backed by world class state of the art infrastructure

HQ Campus
90 acres in Bangalore where most of Syngene's capabilities are housed today

Biologics Expansion
HQ Campus Biologics Manufacturing plant scale:
Mammalian- ~100-2000L
Microbial - ~200-500L

R&D Expansion Genome Valley, Hyderabad, India commenced operation in Aug 2019

API Mfg Expansion
Commercial Manufacturing to support product launch in Mangalore, India - Commenced operation in March 2020; Capacity: 70KL; Reactor size: 2-12KL

Agile and experienced workforce supported by our commitment to continuous learning

~6000
strong pool of employees

Environment that engages our employees and enables them to grow

27%
female employees vs 16% in FY16

Enriching talent pool

- Started Syngene Training Academy (STA) to make the transition smoother for new campus hires and equip them with essential skills

Encouraging development of life skills and technical expertise

- Internally developed training modules tailored to our business and the specific needs of our employees

Fostering inclusion and diversity

- Equal opportunity employer, proactively promoting inclusion and diversity across our workforce to get the best talent mix

Celebrating leaders and leadership

- Bringing out leadership qualities in people and celebrating leaders is one of the key focus areas.
- Key leadership and development interventions include Emerging Leaders Development Program (ELDP), People Managers Forum and Leadership
- Excellence and webinar series.

~5300 scientists delivering quality output and creating competitive edge



Harnessing digitization and automation

Generating reliable and retrievable data by using advanced technology platforms.



Certification as per ISO 13485:2016, ISO/IEC 27001 and ISO 9001:2015 requirements

Strategic Sourcing – agility and resilience that makes a difference

Our dedicated Strategic Sourcing professionals have the expertise and experience to work closely with our global supplier base to ensure timely delivery of supplies for smooth operations of the company, while ensuring strict adherence to quality and regulatory compliances.

e-procurement: Select, monitor and manage suppliers through the Vendor Evaluation System & the other digital tools

Logistics: Provide customized solutions for time-sensitive shipments and ensure product delivery at the fastest possible time while meeting local and international regulations

Commercial: Work as per the rules of the various governmental departments to ensure timely approvals, and to maintain requisite business licenses

Inventory management: Manage receipts, issues, handling and accounting of the materials and identify trends and adjust plans to optimize the supply chain

Procurement transformation

- Optimized demand forecasting, ordering and delivery on a just-in-time basis
- Building deep understanding of products markets and suppliers to obtain optimum pricing
- Improving speed of order processing and turnaround times

Digitalization

Increased transparency, efficiency, and traceability in the procurement lifecycle with process automation

AI based automation

Implementation of AI-enabled robotic process automation (RPA), covering both GMP and non-GMP materials and services

Operational excellence is a way of life

Building Right Philosophy	Building Robust Process	Building Sustenance
• **LEAN & SIX SIGMA** is a belt certification program wherein black belt training is done by ASQ South Asia. • **5s** is an initiative scaled up to cover functional units • **GEMBA WALK** was established and integrated with EHSS and Quality parameters. • **KAIZEN was** launched as a part of SQDECC, a central repository to review and implement using cross-function team • **WHY CULTURE,** problem-solving culture	• **Simplification of order-delivery processes.** • **LEAN LABORATORY** improving Lab productivity. • **QUALITY BY DESIGN** identifies the risk while executing critical steps	• **Right culture with high focus on** safety, quality and customer service. • **SQDECC -** New initiatives - Introduced quarterly audits • **''SynZero'' new platform to report unsafe conditions.** • **Anytime Audit Readiness**



3 Strategic Advantages

Syngene

Syngene's Strength

A Global CRO/CDMO
- Integrated Drug Discovery, Development and Manufacturing service provider
- Small and Large Molecules, ADCs, Oligonucleotides
- Listed on Indian Stock Exchanges (NSE and BSE)

IP Position
- IP can be fully assigned to clients
- Strong track record of Data Integrity and Security
- Over 400+ patent assignments by clients recognizing Syngene

Quality Focus
- Quality driven organization
- Excellent track record of compliance with global regulators
- US FDA, EMA and PMDA approved, GLP Certified, AAALAC Accredited facility
- 15+ regulatory and ~250 client audits in the last 3 years



Scientific Ecosystem
- 2 Mn sq. ft.world-class R&D and Manufacturing infrastructure
- Sites in Bangalore, Mangalore, and Hyderabad
- ~5300 qualified scientists including ~500 PhDs
- Highly effective supply chain practices
- Large molecule capacity of 10,000 L and small molecule capacity of 70,000 L

Marquee
+ ~ 420 active clients
- Partnering with large / mid-size / emerging BioPharma (EBP) and other industries
- Clients concentrated in US, Europe & Japan
- Track record of working with diverse industry sectors

Track Record
- Collaborations and partnerships to deliver numerous clinical candidates
- Delivery history for integrated CMC programs towards FIH and beyond

Strong track record of growth and profitability



FY18 to FY22 - CAGR 16%



FY18 to FY22 - CAGR 13%



FY18 to FY22 - CAGR 8%

*PAT is before exceptional items

Multiple levers for growth going ahead

Expand/Extend Existing Clients
- High service integration
- Dedicated centers model

Engage New Clients
- Tailored service offerings and dedicated personnel



Capacity Expansion
- Consistent investment
- FTE services, manufacturing, formulation, biologics, stability

Offtake in commercial manufacturing in both biologics and small molecule API

Integrated Drug Discovery
- Go to model, with an integrated scientific solution provider, delivering end to end client's requirements

Capability Additions
- New capabilities across multiple domains incl. the allied sectors
- Stability, analytical and bio-analytical services, viral testing, Oligonucleotide bioinformatics
- New platforms: ADC,CAR-T,PROTACs

Our end-to-end platform enables us to be a 'one-stop-shop' for discovery, development and manufacturing (small and large molecules)



Discovery	Development	Manufacturing
Chemistry	Drug Substance Development	Clinical Supplies
Biology	Drug Product Development	
	Integrated Drug Substance – Drug Product	HPAPI
Safety Assessment		Specialty Molecules
Integrated Drug Discovery	HPU* (Phase 1)	Commercial Supplies
	Bio Analytical Lab (Large Molecules)	
Therapeutic Antibody Discovery & Engineering; Cell Line Development	Stability & Analytical Services	
	Bioprocess Development, Process Characterisation, Clinical Manufacturing (Microbial & Mammalian)	
Research Informatics: Bioinformatics, integrative analysis, target dossiers, systems modeling, cheminformatics and AI		

** Human Pharmacology Unit*

Discovery Services






	Target Identification and Validation	Hit Identification	Hit to Lead	Lead Optimization	IND Enabling	IND / Ph1 DE
Biology Translation	**Target ID** 1. Pathway analysis 2. Omics 3. Knock-in / knock-out **Hypotheses:** 1. Therapeutic 2. Mechanistic 3. Target Engagement	***In vitro* assays:** 1. Biochemical 2. Orthogonal 3. HTS Formats	***In vitro* assays:** 1. Cellular Mechanistic 2. Cellular Functional 3. Relevant Off-Target(s) ***In vitro* ADME assays:** 1. Protein Binding 2. Metabolism 3. CYP Inhib/Induct **Research Operating Plan:** 1. Assay Priority 2. Key Studies 3. Critical Path	***In vivo* assays/studies:** 1. PK (R/NR) 2. PD, PK/PD 3. Efficacy **Hypothesis:** 1. Patient Selection	**Later Translational:** 1. PK/PD/Efficacy 2. Refinement of patient selection hypothesis 3. Biomarkers **Human Dose Projection** 1. h-PK Projection 2. PK/PD/Efficacy data 3. Safety/Tox data	**Ph1-HV or Patient (as appropriate):** 1. Exposure 2. PD
Chemistry Development Formulation Clinical Development		**HTS/DEL/Fragments/Virtual Screening** 1. Library Design/Synthesis/ Maintenance 2. Hit validation, Resynthesis 3. Series Qualification, Prioritization	**Optimization:** 1. Biochem/Cell Potency 2. Selectivity 3. Phys/Chem Properties 4. In Vitro/Vivo Tool Cmpds	**Optimization:** 1. Tgt Optimal h-Profile 2. Candidate Selection 3. Backup Strategy	**Drug Substance (DS, aka API)** 1. Route Scouting (define specs) 2. Scale Up 3. Manufacture/Stability	**Drug Product (DP)** 1. Pre-Formulation Studies 2. Ph1 Suitable Formulation 3. Prototype/Stability 4. Manufacture/Stability 5. IND, BA/BE, DDI and Phase 1 clinical trials 6. GCP Bioanalysis
Safety Assessment			***In vitro* Safety:** 1. hERG 2. Ion Channels	**Tox-Suitable Formulation (maximize exposure)**	DRF Tox (R/NR) Bioanalysis GLP Tox (R/NR) GLP Bioanalysis	MTD or RP2D (as appropriate)

Informatics → **Iterative Data Analysis and Interpretation, Models, Hypothesis Generation**

Development Services and Manufacturing Services





	Developability Assessment	Development phase	Clinical Phase			Registration/process validation	Commercial batches
			Phase I	Phase II	Phase III		
Safety Assessment	Early PK, MTD/DRF studies, Exploratory Tox	• IND enabling GLP Tox studies: Ames, Chromosomal aberration, Micronucleus tests, Pivotal repeat dose (Rodent and Non- rodent) • Safety Pharmacology: CNS, Respiratory, CV Telemetry, hERG		• NDA enabling studies: Sub- chronic and Repro-tox studies • Local Tolerance study	Chronic and Carcinogenicity study		
Chemical Dev and Manuf.	• Route scouting • Process safety evaluation • Scalability	• Fit to purpose Process dev • Material supply • Impurity identification • Enable and scale • Tox material delivery	• Process dev , robustness and safety study • Unit operation studies • Impurity synthesis & characterization • DS clinical batch supply			• Process DOE, QBD and scale up studies • Process Risk assessment • FMEA analysis • Registration and process validation batches manuf.	Commercial batches manuf. and packaging
Formulation Dev and Manuf.	• Pre-formulation • Salt polymorph screening • Excipient compatibility	• Solid Oral & Injectable dosage forms • Enabling formulation technologies	Clinical Supplies for all phases • FIH formulation for Phase 1/2A • Final dosage form for Phase 2B/3 and onwards				
Analytical Services	Methods for Pre-formulation and Bio-analytical	• Methods for Intermediate, Final DS, DP • Forced degradation studies • Solid state characterisation	• Phase appropriate method validation for DS & DP (microbial methods) • Specifications for DS & DP • In process and Finished product analysis • Final batch release with COA • Reference standard , Impurities, Isolation and characterisation			Robustness of Analytical methods and full validation as per ICH	Analysis of commercial batches
Stability Services	Selection of suitable container closure system & packaging	• Development stability studies	• ICH stability for all phases • Shelf life Estimation • Re-test extension			Stability study of registration/ process validation batch	Stability study of commercial batches
Clinical Development			• Human Pharmacology Unit (Phase I/BE studies) • Clinical Trial Services – full solution provider for conducting trials in India • Central Lab Services including regulated bioanalytical lab • Clinical data management, biostatistics and medical writing				

Regulatory Support

Biologics Development and Manufacturing services





	Developability Assessment	Development phase	Clinical Phase			Registration/process validation	Commercial batches
			Phase I	Phase II	Phase III		
Process & analytical development	• Cell line development / selection • Process screening • Process characterization	• Clone to GMP • Upstream process Optimization • Viral clearance studies	• Process DOE, robustness and safety study • Unit operation studies • Impurity synthesis & characterization • DS clinical batch supply (non-GMP clinical & GMP) • CMC & regulatory support • Method development & testing			• Process risk assessment • FMEA analysis • Tech transfer package	• Commercial batches • manufacturing and packaging • technical support
Scale-up & QC/QA	• Methods for pre-formulation and bio-analytical	• Methods for intermediate, final DS, DP • Critical to quality parameter identification • Forced degradation studies	• Clinical phase process development & supply • Specifications for DS & DP • In process and finished product analysis • Viral clearance studies • Packaging and ICH storage stability and shelf-life estimation			• 3-Lot testing & equipment validation • Cleaning validation studies • Pre-audit preparation	• QC/QA analysis & release of commercial product w/ COA • Stability analysis • Root cause Investigation & CAPA management
Commercial production & supply chain	• Early screening of asset capability and capacity	• Capacity utilization planning	• Late phase clinical supply using manufacturing scale equipment • Supplier identification • Waste management plan • CAPEX requirement identification			• Supplier qualification • Pre-audit preparation • Protocol documentation • Master batch record development • Operation training	• Sales and operations planning • Delivery / logistics • Customer & regulatory audits • Process improvement & Regulatory filing updates

Regulatory Support

Led by a globally experienced management team

Jonathan Hunt
Managing Director and Chief Executive officer

Experience

AstraZeneca

Dr. Mahesh Bhalgat
Chief Operating Officer

Sanofi, Amgen, Monsanto

Sibaji Biswas
Chief Financial Officer

Vodafone, Hutchison Telecomm

Ashu Tandon
Chief Commercial Officer

IQVIA
Accenture

Sanjeev Sukumaran
Chief Human Resources Officer

Thomson Reuters

Alok Mehrotra
Chief Quality Officer

Experience

Reckitt Benckiser, PepsiCo, Godrej, DRL

Dr. Kenneth Barr
SVP Discovery Services

FORMA
Merck

Dr. Jan-Olav Henck
SVP Development Services

Bayer AG, SSCI, Aptuit

Alex Del Priore
SVP Manufacturing

Johnson Matthey

Advised by Our Board of Directors

Kiran Mazumdar Shaw
Non-Executive Chairperson

Experience

Chairperson of Biocon Limited, ~45 years of experience in the field of biotechnology

Jonathan Hunt
Managing Director and Chief Executive officer

~30 years of experience in the global biopharmaceuticals industry

Dr. Carl Dcicco
Independent Director

Chief Scientific Officer in Foghorn Therapeutics

Professor Catherine Rosenberg
Non-Executive Director

Professor in electrical and computer engineering at the University of Waterloo, Canada

Vinita Bali
Independent Director

Chief Executive Officer & MD of Britannia Industries from 2005 to 2014

Paul Blackburn
Independent Director

Experience

40 years+ experience in the field of finance

Sharmila Abhay Karve
Independent Director

Retired as audit partner from Price Waterhouse

Dr Vijay Kuchroo
Independent Director

Founded five biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals

Kush Parmar
Independent Director

Managing Partner at 5AM Ventures, a life sciences venture capital firm

Committed to sustainability

Safety is at the heart of everything we do

- Accredited with ISO 45001:2018 for its Occupational Health and Safety (OH&S) measures
- Risk assessments are the integral part of our operation - a proactive approach in incident prevention
- 21,761 man hrs of regular safety training under Kavach, our flagship safety program considerable improvement across several safety metrics
- 13.7 million manhours without Lost Time Incident (LTI) on rolling 12-month basis for FY22

Increased incident reporting	**Reduction of incidents**
Improved risk control measures	**Improved general safety perception**

Committed to environmental protection

- Accredited with ISO 14001:2015 for its effective Environment Management System (EMS)
- **34,000 KL** of water conserved through effective rainwater harvesting as well as recycling of used water; up 61% from FY21
- **92%** of the total waste generated are recycled in an environment-friendly manner for FY22
- **3-R's** Operations constantly monitored to identify opportunities to reduce, reuse, and recycle waste
- **67,000 tons** of carbon dioxide emissions reduced in FY22,up 26% from FY21
- **74 Mn KWH** of electricity usage through Green energy sources; up 18% from FY21
- **85%** of Energy consumption is through green energy sources in FY22

Refer to the CSR link on our website to know about our corporate social responsibility pursuits on healthcare, education, environment, rural development

All figures are as on March 31, 2022, unless otherwise specified

ESG report -a step towards delivering a transparent account of our progress on financial and non-financial parameters

ENVIRONMENTAL	SOCIAL	GOVERNANCE
• Environmental Governance through three areas energy use, Water conservation, and waste management. • **Energy** maximizing the use of renewable resources and reducing the use of energy in offices, laboratories, and manufacturing units. • **85%** of electricity was procured from renewable sources delivering a reduction in greenhouse gas emissions of approximately 67013 tCO 2 • **Water** focusing on conserving and promoting responsible use of water is a high priority and a zero discharge policy governs the management of wastewater and effluent • **Waste** proactive approach to sorting and facilitating appropriate recycling, reuse and disposal of waste is critical.	• **Safety** • Centralized team of EHSS professionals embedded in every operational division. • Kavach safety program with specialized stream • **Employees** • Equal opportunity with 27% female employees. • Varied range of employee benefits • Zero tolerance to child labor, forced labor, discrimination or violation of human rights • Large learning & development platform • **Diversified** leadership and employee base • Healthcare service to the underprivileged section • Best corporate foundation award.	• Quality assurance • Continuous improvement • Responsible procurement • Supplier code of conduct • Supply chain sustainability

We have consistently received industry recognition for our scientific capability and best practices

2018

- **Bio-Excellence Award 2018:** At Bengaluru Tech Summit, Bengaluru
- **Best Bioprocessing Excellence Award 2018** - At 5th Biologics Manufacturing Asia, Singapore
- **Healthcare Company of the Year 2018:** At the 7th Annual VC Circle Awards 2018, Mumbai
- **HR Excellence Award 2018 'For Best Talent Management Strategy':** World HRD Congress, Mumbai

2019

- Ranked as one of the **25 fastest growing companies in India** by Outlook Business
- **CMO Leadership Awards 2019** - Presented by Life Science Leader Magazine
- **FICCI CSR Award for Environmental Sustainability** -At the 17th Edition of the awards in New Delhi
- **Safe Workplace Champion Award** - At the 8th Manufacturing Supply Chain Summit and Awards
- **Best Leadership Development Program for Middle Management Award** - At the 6th Global Training and Development Leadership Awards
- **India Pharma Award 2019** - For "Excellence in Contract Research and Manufacturing Services" at CPhI & P-MEC India Expo.
- **Utthama Suraksha Puraskar 2019 - (Pharma and Chemical Manufacturing Category) by National Safety Council of India (NSCI). Leadership Awards**

2020

- **CMO Leadership Award Winner 2020 -** under Categories: Capabilities, Compatibility, Expertise and Service
- Bioprocessing Excellence Awards 2020 in the category 'Bioprocessing Excellence in South Asia—Viral Clearance and Safety Testing'
- **Great Place to Work Certified™ Company**
- (ASSOCHAM) CSR & NGO Awards 2020 for our contribution to COVID-19 relief work in Karnataka.

2021

- **Dream Companies to Work Award** at the 29th Edition of the World HRD Congress Awards.
- **Asian Leadership Award for Excellence in Branding and Marketing** in the Contract Research Development and Manufacturing category
- **CRISIL awards Syngene Top score among Indian Pharma:** for Environment Safety Governance (ESG)
- **Syngene ranked #69 in Fortune India magazine's** list of 'Top 100 Indian wealth creators 2021'
- **India Pharma Awards 2021** for Operational Excellence: Manufacturing organized by Informa Markets, India
- **Best Governed Company in the Listed Segment: Medium Category** at the 21st National Awards for Excellence in Corporate Governance by The Institute of Company Secretaries of India (ICSI)
- **Most Innovative New Learning Programme** at the L&D Vision & Innovation Award organized by Transformance Forums
- **Mahatma Award 2021** Under Health & Wellbeing Category
- **Best Corporate Foundation Award** at the World CSR Congress

2022

- **CMO Leadership Awards 2022** Received 6 awards for all categories, including Capabilities, Compatibility, Expertise, Quality, Reliability and Service
- **CMO Leadership Award Champion 2022** Additional Recognition received in CMO Leadership Awards 2022 for top performance in all categories

Proactively managing risks through robust risk management framework

Syngene has a risk management framework to identify, monitor, report and manage risk across the business.
Every risk owner monitors and manages risks relevant to their area of responsibility.

Risk Owner

- Identify and mitigate risk in respective business areas

Executive Committee (EC)

- Sign off on Enterprise Risk Framework – Annually
- Review and approve the key updates to enterprise risks and deep dive into few risk areas every quarter

Risk Committee

- Sign off on Enterprise Risk Framework – Annually
- Ensure that appropriate measures are in place to mitigate the risks
- Review key updates to enterprise risks and deep dive into few risk areas every quarter

Board of Directors(BOD)

- Provide strategic direction on mitigation of risks
- Ensure principal risks are properly managed

Risk identification → **Risk assessment** → **Risk analysis and rating** → **Risk mitigation** → **Monitoring and reporting**

Refer Annual report for complete risk profile and risk mitigation strategy

4 Financials

Syngene

Q4 financial highlights

Particulars	Q4 FY22	Q4 FY21	YoY Change	Q3 FY22	QoQ change
Revenue from Operations	**7,581**	**6,586**	***15%***	**6,414**	*18%*
Other Income	147	184	*(20%)*	129	*14%*
Total Revenue	**7,728**	**6,770**	***14%***	**6,543**	*18%*
Material and Power Costs	2,325	1,762	*32%*	1,898	*22%*
Employee Costs	1,736	1,826	*(5%)*	1,888	*(8%)*
Foreign exchange (gain)/loss, net	(91)	(47)	*94%*	(199)	*(54%)*
Other Expenses	1,108	891	*24%*	793	*40%*
EBITDA	**2,650**	**2,338**	***13%***	**2,163**	***23%***
EBITDA Margin	***34%***	***35%***		***33%***	
Depreciation and finance cost	859	766	*12%*	879	*(2%)*
PBT	**1,791**	**1,572**	***14%***	**1,284**	***39%***
Tax on above	313	194	*61%*	244	*28%*
PAT before exceptional item	**1,478**	**1,378**	***7%***	**1,040**	***42%***
PAT Margin	***19%***	***20%***		***16%***	
Exceptional item, net of taxes*	-	228		-	
PAT after exceptional item	**1,478**	**1,606**	***(8%)***	**1,040**	***42%***

**Exceptional item is in relation to receipt of insurance claim in Q4FY21*

FY22 financial highlights

Particulars	FY22	FY21	YoY Change
Revenue from operations (excl export incentives)	**26,042**	**21,843**	**19%**
Other Income	528	646	(18%)
Total Revenue	**26,570**	**22,489**	18%
Material and power costs	8,138	5,839	39%
Employee costs	7,181	6,602	9%
Foreign exchange (gain)/loss, net	(548)	(171)	220%
Other Expenses	3,310	2,855	16%
EBITDA	**8,489**	**7,364**	15%
EBITDA Margin (%)	**32%**	**33%**	
Depreciation, Interest and tax	4,278	3,543	21%
Profit After Tax before exceptional item	**4,211**	**3,821**	10%
PAT Margin (%)	***16%***	***17%***	
Exceptional Items, net of taxes [3]	(253)	228	
Profit After Tax after exceptional item	**3,958**	**4,049**	(2%)

Balance Sheet Highlights

As on 31st March 2022

Shareholders' funds	32,976
Net Fixed assets	27,392
Other net assets [1]	(1,741)
Net cash/(debt) [2]	7,325
Total Use of Funds	32,976

(1) Other Assets calculated as (Inventories + Trade Receivables + Unbilled Revenues + Advance Tax + FX premium less (Trade payables + Others current liabilities) at the end of the year
(2) Net cash / (Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short-term borrowings + Long-term borrowings) at the end of the year
(3) Exceptional item in FY22 is in relation to reversal of services export incentive related to FY20 in line with Government notification. In FY21 relates to receipt from insurance claim

All figures in Rs. Mn unless otherwise specified

5 Shareholding and Share Information

Syngene

Biocon Group and Syngene

Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company

Syngene, a subsidiary of Biocon Limited, was established in 1993 as India's first Contract Research Organization - Company has 25 years plus of unparalleled experience in novel molecule discovery, development and manufacturing services

Biocon Biologics, another subsidiary of Biocon Limited, consolidates the development, manufacturing and commercialization operations of Biocon's biosimilars business

Syngene

Integrated services:

- Discovery
- Development
- Manufacturing small/large molecules



- Product Based
- Biosimilars
- Formulations and Compounds
- Alternative Therapeutic Drugs

Biocon

Biocon Biologics

Shareholding and Share Information

Syngene's Shareholding Pattern*



Syngene's Share Information*

NSE Ticker	SYNGENE
BSE Ticker	539268
Market Cap (Rs. Mn)	2,39,516
% free-float	29%
Free-float market cap (Rs. Mn)	69,268
Share Outstanding (Mn)	401
3M ADTV ^ (Shares)	4,45,313
3M ADTV ^ (Rs. Mn)	261

*As on 31st March 2022

^ NSE Average Daily Traded Volume / Value

For more details

Visit our website www.syngeneintl.com

https://twitter.com/SyngeneIntl

https://www.linkedin.com/company/syngene-international-limited

https://www.facebook.com/syngeneintl/

https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ

IR Contact:
Krishnan G
+ 91 806 891 9807
investor@syngeneintl.com

Media Contact:
Shotorupa Ghosh
+91 8450977080
Shotorupa.ghosh@syngeneintl.com

Syngene

Putting Science to Work

Thank you